BON Stock Overview
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Boiron SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €33.55 |
| 52 Week High | €56.60 |
| 52 Week Low | €32.20 |
| Beta | 0.47 |
| 1 Month Change | 4.19% |
| 3 Month Change | -18.07% |
| 1 Year Change | -17.36% |
| 3 Year Change | -15.60% |
| 5 Year Change | -33.70% |
| Change since IPO | 123.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| BON | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.4% | -2.9% | -2.5% |
| 1Y | -17.4% | -31.3% | -0.4% |
Return vs Industry: BON exceeded the German Pharmaceuticals industry which returned -29.6% over the past year.
Return vs Market: BON underperformed the German Market which returned 1% over the past year.
Price Volatility
| BON volatility | |
|---|---|
| BON Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BON's share price has been volatile over the past 3 months.
Volatility Over Time: BON's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1932 | 2,813 | Valérie Lorentz-Poinsot | www.boiron.fr |
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.
Boiron SA Fundamentals Summary
| BON fundamental statistics | |
|---|---|
| Market cap | €583.37m |
| Earnings (TTM) | €47.62m |
| Revenue (TTM) | €517.36m |
12.3x
P/E Ratio1.1x
P/S RatioIs BON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BON income statement (TTM) | |
|---|---|
| Revenue | €517.36m |
| Cost of Revenue | €135.11m |
| Gross Profit | €382.25m |
| Other Expenses | €334.63m |
| Earnings | €47.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 11, 2024
| Earnings per share (EPS) | 2.74 |
| Gross Margin | 73.88% |
| Net Profit Margin | 9.20% |
| Debt/Equity Ratio | 0.5% |
How did BON perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield40%
Payout RatioDoes BON pay a reliable dividends?
See BON dividend history and benchmarks| Boiron dividend dates | |
|---|---|
| Ex Dividend Date | Jun 03 2024 |
| Dividend Pay Date | Jun 05 2024 |
| Days until Ex dividend | 46 days |
| Days until Dividend pay date | 48 days |
Does BON pay a reliable dividends?
See BON dividend history and benchmarks